Oncomatryx Biopharma, S.l.

Progenika Biopharma S.a.

Brainco Biopharma, S.l.

Laureano Simon

Antonio Martinez

Roland Kontermann

Klaus Pfizenmaier

Diego Tejedor

Myriam Fabre

Cristina Ferrer

Jorge Ochoa

Monica Lopez

David Arteta

Madeleine Sombekke

Bernard Uitdehaag

Chris Polman

Salvador Pena

Sergio Escorza

Marcelo Ferrer

Maria Uribarri

David Garcia

Marta Artieda

Bart A Crusius

The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I:A-(L-D)p&#x2003;&#x2003;(I)or a pharmaceutically acceptable salts or solvates thereof,wherein:A is an antibody that selectively binds FAP;L is a linker;D is a drug comprising a cytolysin or a Nigrin-b A-chain; andp is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Antibody-drug conjugates and immunotoxins

The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

The present invention provides a method for detecting the presence or absence of, or for discriminating between, blood type variants, including RHD*r's, RHD*DIIIa, RHD*DIVa-2, RHCE*csand RHCE*ce733G. The method comprises genotyping a sample obtained from a human subject at one or more positions in intron 7 of the RHD gene and/or in intron 7 of the RHCE gene. The invention also provides products, in particular, probes, primers and kits for use in the method of the invention.

Discrimination of blood type variants

A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.

Transgenic animal model of mood disorders

A method for determining the presence or absence of a genetic segment of interest, such as an exon, an intron or a promoter, in a DNA-containing sample, and probe sets for use in such methods, including probe sets comprising oligonucleotide probes having nucleotides sequences selected from those of SEQ ID NOS: 1-101.

Probes and methods for determining the presence or absence of genetic segments

The invention relates to methods of evaluating MS severity based on analysis of single nucleotide polymorphisms (SNPs) and to products and kits for use in such methods. The methods include a method of assessing a multiple sclerosis disease severity phenotype in a human subject having multiple sclerosis, by determining the genotype of the subject at one or more positions of single nucleotide polymorphism (SNP) selected from: rs2107538, rs1137933, rs1318, rs2069763, rs423904, rs876493, rs10243024, rs10259085, rs1042173, rs10492503, rs10492972, rs12047808, rs12202350, rs12861247, rs13353224, rs1350666, rs1555322, rs1611115, rs17641078, rs1805009, rs2028455, rs2032893, rs2049306, rs2066713, rs2074897, rs2076530, rs2187668, rs2213584, rs2227139, rs2234978, rs2239802, rs2395182, rs260461, rs28386840, rs3087456, rs3135388, rs3741981, rs3756450, rs3781202, rs3787283, rs3808585, rs4128767, rs4404254, rs4473631, rs4680534, rs6077690, rs6457594, rs6570426, rs659366, rs6917747, rs7208257, rs7528684, rs7577925, rs762550, rs7956189, rs7995215, rs8049651, rs8702, rs9808753 and rs987107, and/or a SNP in linkage disequilibrium with any one of said SNPs.

Genotyping tool for improving the prognostic and clinical management of MS patients

Growing community of inventors

Derio, Spain

Laureano Simon